GLP-1 Pathway: How It Works and What Medicines Do to It (October 2026)

01 · The core answer

The GLP-1 signalling pathway, step by step

The pathway runs from the gut to the pancreas and brain in a clear sequence.

The effects on appetite, stomach emptying and insulin are the ones a licensed GLP-1 medicine builds on.¹ For the cell-level detail, see our guide to GLP-1 receptor signalling.

02 · What to do next

Is this relevant to you?

It matters if you are considering a treatment that acts on this pathway. Mounjaro is licensed in the UK for weight management in adults and for type 2 diabetes, and it is supplied only after a consultation reviewed by a GPhC-registered prescriber.¹

If you want to see whether treatment suits you, start with the Mounjaro pen prices and consultation page, where your first 2.5mg pen costs £129.99 with code FIRST40 (standard price £169.99). You can also read about our wider weight loss clinic approach.

03 · DPP-4 and degradation

DPP-4 and why natural GLP-1 is so short-lived

DPP-4 is an enzyme that breaks down natural GLP-1 within minutes of release.

This is where the "DPP-4 GLP-1 pathway" idea comes from.

Mounjaro is a once-weekly injection. Its active ingredient, tirzepatide, stays in the body long enough that after a final dose it takes roughly four to five weeks to clear, and there is no way to speed this up.¹

04 · Brain and reward pathway

What GLP-1 does in the brain: the reward pathway

GLP-1 signals reach the brain's appetite-control areas, which is how the pathway contributes to feeling full. In practice, most people on a GLP-1 medicine feel fuller sooner and less hungry between meals.¹

If your mood drops or you have distressing thoughts after starting treatment, tell your prescriber. If you have thoughts of harming yourself or ending your life, get help straight away. Call 999 or go to A&E if you are in immediate danger. In England you can call NHS 111 and choose the mental health option, any time. You can also call Samaritans free on 116 123, day or night.

05 · Does it cause diabetes?

Can the GLP-1 pathway cause diabetes?

The pathway is part of normal blood-sugar regulation, and the evidence does not show that it causes diabetes. Mounjaro is licensed for type 2 diabetes, where it improves blood sugar control (HbA1c) and supports weight loss.¹

If you have type 2 diabetes, treatment and monitoring are coordinated differently, so tell your prescriber and your usual diabetes team to keep care joined up.¹ If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines. Your prescriber or diabetes team should guide this.

06 · How Mounjaro acts

Where Mounjaro fits in the pathway

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹

This dual action distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide (Wegovy/Ozempic).¹ You can compare it with the Wegovy pen, or read more about GLP-1 technology.

In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages. Individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.²

07 · Boosting GLP-1 naturally

Foods, supplements and "natural GLP-1" products

Products marketed as natural GLP-1 boosters are not equivalents and are not substitutes for prescribed treatment. Products marketed as natural GLP-1 boosters are not assessed or prescribed like a medicine, and their dosing is not standardised.

If you are curious, our guides cover GLP-1 smoothies, a GLP-1 prebiotic and the GLP-1 plaster claims. Low-cost supplements come with no clinical oversight, so treat dramatic weight-loss claims with caution.

08 · NHS and private access

Getting treatment that acts on this pathway

Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴

Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting. Our service is a free online consultation reviewed by a GPhC-registered prescriber, with free next-day tracked delivery and ongoing monthly reviews.